New data indicates that retatrutide, a dual-action medication, could represent a considerable step in size loss . This treatment combines the properties of a GLP-1 receptor and a GIP agonist , potentially offering a greater outcome than current approaches . Patient assessments have shown encouraging outcomes, including considerable declines in wei